Sino Biopharmaceutical Limited Announces Landmark Clinical Results for M701 “CD3/EpCAM Bispecific Antibody” at ASCO 2026
Key Highlights
- Groundbreaking Clinical Data Presented: Sino Biopharmaceutical Limited (HKEX: 1177) disclosed significant results from two clinical trials of its innovative drug M701 at the prestigious 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
- First Immunotherapy-Based Local Treatment Validated in Large-Scale Trials: M701, developed by subsidiary Chia Tai Tianqing Pharmaceutical Group Co. Ltd., marks the first immunotherapy for malignant effusions in advanced cancer to show clear benefit in major clinical studies.
- Positive Market Impact: The marketing application for M701 was accepted by China’s National Medical Products Administration (CDE) in May 2026, positioning the drug as a potential new standard of care for malignant pleural effusion (MPE) and malignant ascites (MA) in China.
Detailed Clinical Study Results
1. Phase III Registrational Study in Malignant Ascites (MA) – “Dayu Trial” (NCT06432296)
- Population: 312 patients with MA caused by advanced epithelial solid tumours (gastric, colorectal, ovarian cancers).
- Design: Randomized, controlled, open-label (2:1 randomization). Study group received intraperitoneal M701 plus systemic therapy; control group received paracentesis plus systemic therapy.
- Primary Endpoint: Puncture-free survival (PuFS): Time from end of core treatment to first re-puncture or death.
- Results:
- PuFS: Median PuFS was 87.59 days (M701) vs 49.96 days (control).
- Time to Next Paracentesis (TTNP): 186.72 days (M701) vs 55.08 days (control).
- Puncture-free survival rates: M701 group had 76.9% (1 month) and 62.0% (2 months), compared to 69.4% and 38.4% for control.
- Quality of Life: Patient-reported outcomes showed M701 significantly delayed deterioration of global health status.
- Safety: Grade ≥3 treatment-related adverse events (TRAEs) were comparable between groups.
- Overall Survival (OS): Similar between groups; the improved ascites control did not compromise OS.
- Clinical Significance: M701 could replace conventional paracentesis and intraperitoneal chemotherapy, offering improved quality of life and durable ascites control.
2. Phase II Study in Malignant Pleural Effusion (MPE) in NSCLC
- Population: 92 NSCLC patients with symptomatic MPE, progressed after at least one line of systemic therapy.
- Design: Study group received thoracentesis drainage plus intraperitoneal M701. Control group received thoracentesis plus cisplatin or thoracentesis alone.
- Results:
- PuFS: Among patients with negative driver mutations, median PuFS was 176 days (M701) vs 42.5 days (control); for platinum-resistant patients, 178 days (M701) vs 53.5 days (control).
- Hazard Ratios: HR 0.34 and 0.67 for the above groups, showing significant benefit for M701.
- Objective Response Rate (ORR) for Pleural Effusion: 64.9% (M701) vs 18.5% (control) for NSCLC patients with negative driver mutations.
- Safety: Grade ≥3 TRAEs: 2.2% (M701) vs 6.4% (control). M701 group mainly experienced anaemia and elevated lipase, while control group saw nausea and vomiting.
- Clinical Significance: M701 provides a novel, high-efficacy, low-toxicity option for MPE patients with negative driver mutations or platinum resistance.
Market and Shareholder Impact
- Filling an Unmet Need: MPE and MA have lacked a standard-of-care. Current treatments (paracentesis, cisplatin, sclerosing agents) suffer from low efficacy, severe toxicity, and poor quality-of-life outcomes. M701 addresses these pain points.
- Novel Mechanism: M701 activates local T cells to eliminate EpCAM-positive tumour cells, minimizing effusion at its source and providing durable symptom relief and recurrence control.
- Innovative Endpoint: Both studies used puncture-free survival (PuFS) as primary endpoint, a quality-of-life-focused metric highly recognized by ASCO and international experts.
- Regulatory Progress: The marketing application for M701 was accepted by the CDE in May 2026, positioning it as the first potential standard of care for MPE and MA in China.
- Competitive Advantage: Compared to catumaxomab (EU-approved): M701 offers superior safety and clinical accessibility. Compared to drainage or local chemotherapy: M701 achieves higher response rates and more durable control.
- Potential Share Price Impact: These results, regulatory progress, and market potential for a new standard-of-care immunotherapy could be highly price sensitive and drive investor interest in Sino Biopharmaceutical Limited.
Board and Management
- Board Chairwoman: Theresa Y Y Tse
- Six executive directors and five independent non-executive directors
Conclusion
Sino Biopharmaceutical Limited has announced potentially transformative clinical data for M701, a first-in-class immunotherapy for malignant effusions. The strong efficacy, favorable safety profile, and acceptance of its regulatory application position M701 as a game-changer in cancer care, likely to influence the company’s share value and investor sentiment.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisers before making any investment decisions. The clinical and regulatory outcomes discussed are subject to further review and approval.
華語版：Sino生物製藥有限公司於ASCO 2026公佈M701雙特異性抗體突破性臨床數據
重點摘要
- 重大臨床數據公佈： Sino生物製藥有限公司（1177.HK）於2026年美國臨床腫瘤學會（ASCO）年會公佈M701創新藥物的兩項重要臨床試驗結果。
- 首個大規模驗證之免疫治療： M701由子公司正大天晴藥業集團開發，是首個針對惡性腫瘤積液的免疫治療，在大型臨床研究中證實有明顯療效。
- 市場影響： M701的上市申請已於2026年5月獲中國國家藥品監督管理局（CDE）受理，有望成為中國惡性胸腔積液（MPE）及惡性腹水（MA）的新標準治療。
臨床詳細結果
1. 惡性腹水（MA）III期註冊臨床試驗（Dayu試驗，NCT06432296）
- 患者人數： 312名因晚期上皮性腫瘤（胃癌、結直腸癌、卵巢癌）引起MA的患者。
- 設計： 隨機、對照、開放（2:1比例）。試驗組接受腹腔內M701+全身治療；對照組為穿刺+全身治療。
- 主要終點： 無穿刺生存期（PuFS）：由核心治療結束到首次再次穿刺或死亡的時間。
- 結果：
- PuFS： M701組87.59天，對照組49.96天。
- 下次穿刺時間（TTNP）： M701組186.72天，對照組55.08天。
- 無穿刺生存率： M701組1個月76.9%，2個月62.0%；對照組分別為69.4%及38.4%。
- 生活質量： 病人自述顯示M701組顯著延遲健康惡化。
- 安全性： ≥3級治療相關不良事件類似。
- 總生存期： 兩組相近，證明M701改善腹水未影響生存。
- 臨床意義： M701有望取代傳統穿刺及腹腔化療，顯著提升生活質量並持久控制腹水。
2. 非小細胞肺癌（NSCLC）惡性胸腔積液（MPE）II期臨床研究
- 患者人數： 92名MPE且至少經一線全身治療後進展的NSCLC患者。
- 設計： 試驗組接受胸腔穿刺+腹腔內M701；對照組為胸腔穿刺+順鉑或僅穿刺。
- 結果：
- PuFS： 無驅動突變患者：M701組176天，對照組42.5天；鉑類耐藥患者：M701組178天，對照組53.5天。
- 危險比： 0.34及0.67，顯著顯示M701療效。
- 胸腔積液客觀反應率（ORR）： 無驅動突變患者M701組64.9%，對照組僅18.5%。
- 安全性： ≥3級不良事件：M701組2.2%，對照組6.4%；M701組主要為貧血、脂肪酶升高，對照組為噁心、嘔吐。
- 臨床意義： M701為無驅動突變或鉑類耐藥MPE患者提供高效低毒的新選擇。
市場及股東影響
- 填補市場空白： MPE與MA長期缺乏標準治療，現有方法療效低、毒性重、生活質量差。M701解決這些痛點。
- 創新機制： M701激活局部T細胞消除EpCAM陽性腫瘤細胞，源頭減少積液，持續緩解症狀並控制復發。
- 終點設計： 兩項研究以PuFS為主要終點，聚焦生活質量，獲ASCO及國際專家高度認可。
- 監管進展： M701上市申請已獲CDE受理，有望成為中國首個MPE及MA標準治療。
- 競爭優勢： 對比catumaxomab（歐盟批准）：M701安全性更佳、臨床易得；對比穿刺或化療：M701反應率更高、積液控制更持久。
- 股價敏感點： 此次臨床、監管進展及市場潛力，有望推動Sino生物製藥股價。
董事會及管理層
- 董事會主席：謝任天
- 六位執行董事、五位獨立非執行董事
總結
Sino生物製藥公布M701臨床數據，有望改變惡性積液治療格局。療效顯著、安全性良好、監管進展順利，將極大提升公司價值及投資者信心。
免責聲明： 本文僅供參考，不構成投資建議。投資者應自行調查並諮詢專業顧問。臨床與監管結果仍待進一步審核及批准。
